InMed Pharmaceuticals to Focus on Pharmaceutical Programs Amid BayMedica Uncertainty
ByAinvest
Friday, Dec 12, 2025 5:33 pm ET1min read
INM--
InMed Pharmaceuticals Inc. reported that the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") could have a material negative impact on BayMedica, a subsidiary of the Company. The Act may prohibit BayMedica's commercial business and inventory of rare, non-intoxicating cannabinoids if it comes into force on November 12, 2026. InMed remains focused on its core pharmaceutical programs, including INM-901 for Alzheimer's disease and INM-089 for age-related macular degeneration. BayMedica is evaluating alternative options to maintain compliance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet